185 related articles for article (PubMed ID: 32623519)
1. Inverse in silico-in vitro fishing of unexpected paroxetine kinase targets from tumor druggable kinome.
Zhou W; Yang H; Wang H
J Mol Model; 2020 Jul; 26(8):197. PubMed ID: 32623519
[TBL] [Abstract][Full Text] [Related]
2. Inverse screening of Simvastatin kinase targets from glioblastoma druggable kinome.
Li Y; Wei X; Wang Q; Li W; Yang T
Comput Biol Chem; 2020 Jun; 86():107243. PubMed ID: 32172201
[TBL] [Abstract][Full Text] [Related]
3. Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.
Han M; Sun D
J Comput Aided Mol Des; 2019 Jul; 33(7):689-698. PubMed ID: 31203490
[TBL] [Abstract][Full Text] [Related]
4. Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
Zhu LX; Liu Q; Hua YF; Yang N; Zhang XG; Ding X
Comput Biol Chem; 2019 Jun; 80():324-332. PubMed ID: 31078911
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of the druggable kinase targets of olmesartan and its analogues from a systematic kinase-chemical interaction profile in atherosclerosis.
Zhuang RJ; Jin WD; Wang XY; Wu XM
J Mol Graph Model; 2018 Mar; 80():211-216. PubMed ID: 29414040
[TBL] [Abstract][Full Text] [Related]
6. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
7. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening.
Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757
[TBL] [Abstract][Full Text] [Related]
8. In silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase.
Tanneeru K; Balla AR; Guruprasad L
J Biomol Struct Dyn; 2015; 33(8):1710-9. PubMed ID: 25245460
[TBL] [Abstract][Full Text] [Related]
9. Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.
He Y
Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900320. PubMed ID: 32285482
[TBL] [Abstract][Full Text] [Related]
10. Computational study of paroxetine-like inhibitors reveals new molecular insight to inhibit GRK2 with selectivity over ROCK1.
Keretsu S; Bhujbal SP; Joo Cho S
Sci Rep; 2019 Sep; 9(1):13053. PubMed ID: 31506468
[TBL] [Abstract][Full Text] [Related]
11. Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6.
De Donato M; Righino B; Filippetti F; Battaglia A; Petrillo M; Pirolli D; Scambia G; De Rosa MC; Gallo D
Sci Rep; 2018 Oct; 8(1):16047. PubMed ID: 30375481
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
14. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
Hantschel O
ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
[TBL] [Abstract][Full Text] [Related]
15. Advanced molecular dynamics simulation methods for kinase drug discovery.
Aci-Sèche S; Ziada S; Braka A; Arora R; Bonnet P
Future Med Chem; 2016 Apr; 8(5):545-66. PubMed ID: 27054816
[TBL] [Abstract][Full Text] [Related]
16. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
Cui YH; Chen J; Xu T; Tian HL
Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
19. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
20. In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: A case study on the cancer MAPK signaling pathway.
Meng L; Huang Z
Comput Biol Chem; 2018 Aug; 75():196-204. PubMed ID: 29803964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
